New Stock News | Zhejiang Jingxin Pharmaceutical (002020.SZ) Hong Kong IPO prospectus has expired.
Zhejiang Jingxin Pharmaceutical Co., Ltd. (abbreviated as Jingxin Pharmaceutical, 002020.SZ) submitted its Hong Kong stock offering prospectus on February 11, 2026, which will expire 6 months later on August 11, 2026.
Zhejiang Jingxin Pharmaceutical Co., Ltd. (abbreviated as Zhejiang Jingxin Pharmaceutical, 002020.SZ) submitted its Hong Kong stock prospectus on February 11, 2026, which will expire on August 11, 2026, six months after submission. CITIC SEC was the exclusive sponsor at the time of submission.
According to previous disclosures in the prospectus, Zhejiang Jingxin Pharmaceutical is an innovation-driven pharmaceutical group, strategically focused on two core disease areas: central nervous system diseases; and cardiovascular and cerebrovascular diseases.
Related Articles
Palo Alto Networks (PANW.US) is actively seeking acquisition opportunities and has attempted to acquire Datadog (DDOG.US) and Okta (OKTA.US).
US Stock Market Move | Kanzhun Ltd. Sponsored ADR (BZ.US) surged over 18% with Q2 revenue increasing by 14.1% year-on-year.
US Stock Market Move | The MSCI index exclusion risk strikes again, and Strategy (MSTR.US) has dropped over 4%.
Palo Alto Networks (PANW.US) is actively seeking acquisition opportunities and has attempted to acquire Datadog (DDOG.US) and Okta (OKTA.US).
US Stock Market Move | Kanzhun Ltd. Sponsored ADR (BZ.US) surged over 18% with Q2 revenue increasing by 14.1% year-on-year.
US Stock Market Move | The MSCI index exclusion risk strikes again, and Strategy (MSTR.US) has dropped over 4%.
RECOMMEND
